ライフサイエンスコーパス: nonmelanoma skin cancer

1 most common cancer type among men (excluding nonmelanoma skin cancer).

2 and 98 patients developed cancer (excluding nonmelanoma skin cancer).

3 mary cause of skin cancer (both melanoma and nonmelanoma skin cancer).

4 rt members, 730 reported 802 SMNs (excluding nonmelanoma skin cancers).

5 global increase in incidence of melanoma and nonmelanoma skin cancer.

6 se may offer a viable therapeutic option for nonmelanoma skin cancer.

7 nscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

8 adiation in sunlight is the primary cause of nonmelanoma skin cancer.

9 t ranged from 48.7% for myeloma to 31.4% for nonmelanoma skin cancer.

10 llowing UV irradiation, the primary cause of nonmelanoma skin cancer.

11 the major risk factor for the development of nonmelanoma skin cancer.

12 c has been associated with increased risk of nonmelanoma skin cancer.

13 psoriasis patients are at increased risk for nonmelanoma skin cancer.

14 on plays a critical role in the induction of nonmelanoma skin cancer.

15 ith no previous history of cancer other than nonmelanoma skin cancer.

16 global increase in incidence of melanoma and nonmelanoma skin cancer.

17 sion, which contribute to the development of nonmelanoma skin cancer.

18 %]), attributable to the higher incidence of nonmelanoma skin cancer.

19 organ transplants have an increased risk for nonmelanoma skin cancer.

20 quitous in skin and has been associated with nonmelanoma skin cancer.

21 porine have an increased risk for developing nonmelanoma skin cancer.

22 ell carcinomas (MCCs), an aggressive form of nonmelanoma skin cancer.

23 anding the pathogenesis of wound healing and nonmelanoma skin cancer.

24 aging nor a higher incidence for sun-induced nonmelanoma skin cancer.

25 lignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers.

26 the most prevalent mutations found in human nonmelanoma skin cancers.

27 n phenotypes and development of melanoma and nonmelanoma skin cancers.

28 or subsequent malignancies, meningiomas, and nonmelanoma skin cancers.

29 ic receptors as a new treatment modality for nonmelanoma skin cancers.

30 a-HPVs) may contribute to the development of nonmelanoma skin cancers.

31 ent of precancerous skin lesions and certain nonmelanoma skin cancers.

32 than heterosexual women to report having had nonmelanoma skin cancer (2001-2005 CHIS: aOR, 0.56; 95%

33 These included 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, a

34 Excluding nonmelanoma skin cancers, 55 second cancers were seen in

35 Importance: Keratinocyte carcinoma (nonmelanoma skin cancer) accounts for substantial burden

36 ctrum strikingly similar to that reported in nonmelanoma skin cancer and characteristic of DNA damage

37 Diagnosis of melanoma or nonmelanoma skin cancer and frequent excisions for benig

38 present in sunlight is the primary cause of nonmelanoma skin cancer and has been implicated in the d

39 pants received a cancer diagnosis, excluding nonmelanoma skin cancer and in situ neoplasms.

40 ntial and increasing risk for SNs, including nonmelanoma skin cancer and meningiomas.

41 Increases in nonmelanoma skin cancer and nonprogressive, reversible r

42 aviolet A dramatically increases the risk of nonmelanoma skin cancer and prior exposure to psoralen+u

43 vation was clear for all main cancers except nonmelanoma skin cancer and was stronger for cancers of

44 e and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-r

45 Two nonmelanoma skin cancers and two major adverse cardiovas

46 of breast cancer or other cancers (excluding nonmelanoma skin cancer), and we completed a personal ba

47 -degree family history of melanoma, previous nonmelanoma skin cancer, and lifetime sunbed use.

48 feature of diseases like psoriasis, eczema, nonmelanoma skin cancer, and melanoma where differentiat

49 ve an increased incidence of viral warts and nonmelanoma skin cancer, and the presence of HPV DNA in

50 rs, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myel

51 Nonmelanoma skin cancers are among the most common human

52 More than a million cases of nonmelanoma skin cancers are diagnosed every year.

53 ecent dramatic increases in the incidence of nonmelanoma skin cancers are largely attributable to hig

54 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the p

55 ohort who had no cancer diagnosis (excluding nonmelanoma skin cancer) at the start of follow-up and r

56 ts an avoidable risk factor for melanoma and nonmelanoma skin cancer - both of which may be lethal.

57 bronchus, and lung; malignant skin melanoma; nonmelanoma skin cancer; breast; cervical; uterine; ovar

58 Administration approved for the treatment of nonmelanoma skin cancers, but it has limited activity ag

59 s that beta-HPV infections may contribute to nonmelanoma skin cancer by increasing the likelihood tha

60 It is clear that melanoma and nonmelanoma skin cancer control programs combining prima

61 ity of Pennsylvania, who were diagnosed with nonmelanoma skin cancer, dermatophytosis, acne rosacea,

62 a causative role in ODC up-regulation during nonmelanoma skin cancer development by binding to and st

63 5 cells) to explore the regulation of ODC in nonmelanoma skin cancer development.

64 There were two reported cases of nonmelanoma skin cancer during the follow up of the tran

65 eningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference ch

66 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

67 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

68 Combined cancer incidence (excluding nonmelanoma skin cancers) from 1987 to 2006 was captured

69 The incidence of both melanoma and nonmelanoma skin cancer has been increasing over the pas

70 ll effect of screening for both melanoma and nonmelanoma skin cancers has not been achieved.

71 The primary end point was the number of new nonmelanoma skin cancers (i.e., basal-cell carcinomas pl

72 riant was also significantly associated with nonmelanoma skin cancer in a U.K. population.

73 ated with a dose-dependent increased risk of nonmelanoma skin cancer in patients treated for psoriasi

74 play an important part in the development of nonmelanoma skin cancer in psoralen + ultraviolet A-trea

75 age/repair and prevention of photodamage and nonmelanoma skin cancer in vitiligo.

76 12-month intervention period, the number of nonmelanoma skin cancers in the 6-month postintervention

77 o, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to rece

78 Nonmelanoma skin cancers, in particular cutaneous squamo

79 same cumulative dose, which may explain why nonmelanoma skin cancer incidence depends more strongly

80 e finding of TRPV4 downregulation in several nonmelanoma skin cancers into context.

81 Nonmelanoma skin cancer is the most common cancer in the

82 While a high risk of nonmelanoma skin cancer is well recognized in solid-orga

83 Nonmelanoma skin cancer, Kaposi sarcoma, and posttranspl

84 The elevated risks of nonmelanoma skin cancers might indicate an association w

85 rved being central nervous system (n = 344), nonmelanoma skin cancer (n = 278), digestive (n = 105),

86 mon type of previous cancer in the donor was nonmelanoma skin cancer (n=776) followed by central nerv

87 Excluding nonmelanoma skin cancers (n = 19) and carcinoma-in-situ

88 le of mitochondrial DNA (mtDNA) deletions in nonmelanoma skin cancer (NMSC) and in cutaneous photoagi

89 erum 25-hydroxyvitamin D levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluate

90 the United States, Europe, and Australia for nonmelanoma skin cancer (NMSC) and melanoma.

91 Protective effects of UV-B radiation against nonmelanoma skin cancer (NMSC) are exerted via signaling

92 ndependently reviewed the DSCMs for residual nonmelanoma skin cancer (NMSC) before and after a brief

93 on-exposed survivors who developed an SN1 of nonmelanoma skin cancer (NMSC) had a cumulative incidenc

94 Nonmelanoma skin cancer (NMSC) has become the most commo

95 accurate measurement of the US incidence of nonmelanoma skin cancer (NMSC) has been difficult.

96 aimed to determine the risk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and

97 was to assess trends in mortality rates for nonmelanoma skin cancer (NMSC) in the United States.

98 Nonmelanoma skin cancer (NMSC) is the most common cancer

99 Patients with a periocular region nonmelanoma skin cancer (NMSC) or a nonperiocular NMSC c

100 ot have a greater than expected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas

101 th 95% CIs for any incident cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1

102 nd squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).

103 e intake and risks of skin cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma

104 d higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell ca

105 Various treatment options exist for nonmelanoma skin cancer (NMSC), including topical agents

106 During Mohs micrographic surgery of nonmelanoma skin cancer (NMSC), inflammation in histolog

107 duced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous ce

108 ng Medicare billing codes and categorized as nonmelanoma skin cancer (NMSC), viral-linked and "other"

109 in a single patient were counted, except for nonmelanoma skin cancer (NMSC), where only the first was

110 player in the development and progression of nonmelanoma skin cancer (NMSC).

111 a and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC).

112 een used as sampling frames for ascertaining nonmelanoma skin cancer (NMSC).

113 cies (malignancies), including and excluding nonmelanoma skin cancer (NMSC); all malignancies were ex

114 in a case-control study of 191 patients with nonmelanoma skin cancer (NMSC; 81 SCC and 110 basal cell

115 Nonmelanoma skin cancers (NMSC) are among the most commo

116 V) have been suspected to be carcinogenic in nonmelanoma skin cancers (NMSC), but the basis for poten

117 Cancer registries usually exclude nonmelanoma skin cancers (NMSC), despite the large popul

118 Nonmelanoma skin cancers (NMSCs) are the most common can

119 ous basal cell and squamous cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient

120 ght to be involved in the initiation of some nonmelanoma skin cancers (NMSCs), particularly in patien

121 des further evidence that for primary facial nonmelanoma skin cancers (NMSCs), recurrence rates with

122 neoplasms, increases the risk of developing nonmelanoma skin cancers (NMSCs).

123 with briakinumab vs. placebo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous

124 ent SMNs were thyroid cancer, breast cancer, nonmelanoma skin cancer, non-Hodgkin's lymphoma, and acu

125 Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who re

126 squamous cell carcinoma (SCC) (often termed nonmelanoma skin cancer or keratinocyte carcinoma [KC])

127 et A is associated with an increased risk of nonmelanoma skin cancer, particularly squamous cell carc

128 lomaviruses (HPVs) have been associated with nonmelanoma skin cancers, particularly in immunocompromi

129 hree patients who underwent Mohs surgery for nonmelanoma skin cancers presented between 2 and 4 weeks

130 an papilloma virus infections and associated nonmelanoma skin cancers, providing additional genetic a

131 a US population-based case-control study of nonmelanoma skin cancer, randomly selected from drivers'

132 that can reduce mortality from melanoma and nonmelanoma skin cancer, screening holds the greatest pr

133 found moderately increased SIR estimates for nonmelanoma skin cancer, smoking-related cancers, and Ho

134 Nonmelanoma skin cancers, such as basal-cell carcinoma a

135 Nonmelanoma skin cancers that required at least 3 Mohs m

136 e exposure to sunlight increases the risk of nonmelanoma skin cancer, the avoidance of all direct sun

137 iolet (UV) irradiation is the major cause of nonmelanoma skin cancer, the most common form of cancer

138 identified Zmiz1 as a candidate oncogene in nonmelanoma skin cancer through a transposon mutagenesis

139 were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and popul

140 tocols and disability, dermatitis, melanoma, nonmelanoma skin cancer, viral skin diseases, and fungal

141 ative incidence of SMNs was 9.3% and that of nonmelanoma skin cancer was 6.9%.

142 A trend toward decreased risk of nonmelanoma skin cancer was found in those harboring a g

143 the 10 most common cancers in the US and of nonmelanoma skin cancer was not increased with TNFalpha

144 Nonmelanoma skin cancer was not observed among irradiate

145 An excess risk of nonmelanoma skin cancer was observed subsequent to both

146 At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidenc

147 role of the Fragile Histidine Triad gene in nonmelanoma skin cancer, we have used reverse transcript

148 n, 66 cases of meningioma and 1,007 cases of nonmelanoma skin cancer were diagnosed.

149 .44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) a

150 SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated.

151 d who had no prior history of cancer (except nonmelanoma skin cancer) were followed prospectively for

152 the incidence of all-type cancer (excluding nonmelanoma skin cancers), which was evaluated using Kap

153 a (MCC) is a highly malignant neuroendocrine nonmelanoma skin cancer, which is associated with the Me

154 IN OUTCOME MEASURES: Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and